Sep 21,2021

Happify Health to Distribute its Clinical-Grade, Intelligent Healing Platform Through Microsoft Azure

Today, Happify Health, a global leader in digital therapeutics for anxiety and depression, announced plans to distribute its library of digital therapeutics, including Ensemble, the first and only transdiagnostic prescription digital therapeutic engineered to treat Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD), through Microsoft Azure.

PRODUCT

#pdt

View Analyst & Ambassador Comments
Go to original news
Sep 23,2021

Neurolief Announces First Patient Enrolled in Clinical Study Evaluating Its Brain Neuromodulation System in Treating Major Depressive Disorder

Neurolief Ltd., a neurotechnology innovator, today announced enrollment of the first patient in its pivotal clinical study evaluating Relivion® DP for the treatment of major depressive disorder (MDD). The Relivion DP is the first non-invasive, multi-channel brain neuromodulation system for at home treatment of neurological and neuropsychiatric disorders. The trial, MOOD, will assess the safety and efficacy of Relivion DP as an adjunctive treatment to pharmaceutical management of MDD in adults who have not achieved satisfactory improvement from antidepressant medications.

PRODUCT

#connected device

View Analyst & Ambassador Comments
Go to original news
Sep 24,2021

DarioHealth to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced that management will participate in a fireside chat during the Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021, at 8:40 ET.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Mar 19,2021

Digital therapeutics company Happify Health secures $73M

Happify Health, a startup building digital therapeutics for people with chronic diseases, raised $73 million in new funding. The investments were led by Deerfield Management Company and included participation from Omega Capital Partners, ION Crossover Partners and existing investors. The fresh capital is part of a new series D and other "related financing," the company said.

FUNDING SERIES D
View Analyst & Ambassador Comments
Go to original news
Mar 22,2021

BehaVR launches VR-enabled stress management programme for clinicians

Virtual reality (VR) digital wellness company BehaVR announced Monday that it is working with healthcare organisations to introduce CenteredVR, a VR-enabled mindfulness and stress management programme, to clinicians and other workers. The company cited early data suggesting that CenteredVR, which was co-developed with Johns Hopkins University, decreased stress levels by 34% on average. According to BehaVR, the programme gradually guides users through a "soothing, immersive VR experience," helping alleviate stress through educational elements and mindfulness practices. It added that the programme, which runs on Pico Interactive's G2 4K S headsets, helps users to "optimise their stress responses, becoming less reactive and more resilient to stressors."

PRODUCT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Mar 31,2021

Big Health doubles its ‘lives covered’ as COVID-19 drives demand and adoption of solutions for good mental health

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced that it more than doubled its number of ‘lives covered’ in 2020 and has recorded industry leading utilization rates upwards of 40%, which compares favorably to the low single digit utilization rates of many telehealth providers.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Apr 06,2021

DTx company Pear inks slew of deals to integrate more digital biomarkers and a digital pill into platform

The Boston-based DTx company has inked collaboration deals with Empatica and KeyWise. Specifically, Pear's collaboration with Empatica will focus on the use of medical-grade wearables and digital biomarkers. The company is looking to use wearables to evaluate a patient's withdrawal symptoms from opioids, alcohol and other substances.

COLLABORATION PARTNERSHIP

#r&d

#software

#connected device

View Analyst & Ambassador Comments
Go to original news
Apr 09,2021

Akili to study EndeavorRx as a COVID-19 brain fog treatment

Akili Interactive, the maker of the FDA De Novo-authorized digital therapeutic EndeavorRx, will be testing its video game ADHD treatment as a potential treatment for cognitive impairments in COVID-19 survivors. Through collaborations with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center, Akili will conduct two separate randomized, controlled clinical studies evaluating EndeavorRx’s ability to target and improve cognitive functioning in COVID-19 survivors who have exhibited a deficit in cognition.

COLLABORATION PARTNERSHIP

#r&d

#cbt

View Analyst & Ambassador Comments
Go to original news
May 11,2021

Large-Scale Study Finds Mental Health App Forms Bond With Users, Marking Key Evolution in Digital Therapeutics

Woebot Health, a pioneer in the development of relational technologies and tools to support mental health, today announced that the results of its most recent study, titled “Evidence of human-level bonds established with a digital conversational agent,” have been published in the open access journal JMIR Formative Research. Among a large sample of 36,070 users, the study provides evidence that Woebot, the company’s proprietary relational agent, establishes a therapeutic bond with users—a construct long thought to be the unique domain of human-to-human interactions. The findings are unprecedented in a commercialized product and could mark a foundational step toward purely digital solutions’ ability to help meet surging demand for mental health care.

CLINICAL STUDY

#chatbot

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
May 25,2021

Big Health and EHIR introduce Mental Health Maturity Index, measuring employer progress toward better mental health

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, along with the Employer Health Innovation Roundtable (EHIR), today introduced the results from the first-of-its-kind Mental Health Maturity Index (MHMI) survey examining the mental health ‘maturity’ levels of 35 large U.S.-based employers covering more than 2.5 million lives.

View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH